Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 31 Mar 2023
Today's top news includes: Cancer cells with thicker glycocalyx are better at evading the immune system. Most brain research is...
Read Full NewsPsychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.
Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.
In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.
1.
Specialized imaging improves overall prostate cancer survival by identifying benefits of salvage radiotherapy
2.
The way that miR-377 inhibits cells that cause prostate cancer.
3.
Mezigdomide Combinations Show Promise in Multiple Myeloma
4.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
5.
What is Mohs micrographic surgery? 8 FAQs about Mohs
1.
Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself
2.
Understanding Iron Saturation Levels in Your Blood
3.
Uncovering New Hope for Follicular Lymphoma Patients
4.
Understanding Bone Metastases: How Long Can Someone Live When Cancer Spreads To The Bones?
5.
HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
4.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge